warfarin and Acute-Lung-Injury

warfarin has been researched along with Acute-Lung-Injury* in 3 studies

Other Studies

3 other study(ies) available for warfarin and Acute-Lung-Injury

ArticleYear
Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal.
    Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:2

    ESSENTIALS: Fresh frozen plasma (FFP) may be associated with a dose-based risk of pulmonary complications. Patients received FFP for warfarin reversal at a large academic hospital over a 3-year period. Almost 20% developed pulmonary complications, and the risk was highest after > 3 units of FFP. The risk of pulmonary complications remained significant in multivariable analysis.. Fresh frozen plasma (FFP) is often administered to reverse warfarin anticoagulation. Administration has been associated with pulmonary complications, but it is unclear whether this risk is dose-related. Aims We sought to characterize the incidence and dose relationship of pulmonary complications, including transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI), after FFP administration for warfarin reversal.. We performed a structured retrospective review of patients who received FFP for warfarin reversal in the emergency department (ED) of an academic tertiary-care hospital over a 3-year period. Logistic regression was used to explore the relationship between FFP dose and risk of pulmonary events.. Two hundred and fifty-one patients met the inclusion criteria. Overall, 49 patients (20%) developed pulmonary complications, including 30 (12%) with TACO, two (1%) with TRALI, and 17 (7%) with pulmonary edema not meeting the criteria for TACO. Pulmonary complications were significantly more frequent in those who received > 3 units of FFP (34.0% versus 15.6%, 95% confidence interval for risk difference 7.9%-8.9%). After stratification by subtype of complication, only the risk of TACO was statistically significant (28.3% versus 7.6%, 95% confidence interval for risk difference 8.2%-16.6%). In multivariable analysis controlling for age, sex, initial systolic blood pressure, and intravenous fluids given in the ED, > 3 units of FFP remained a significant risk factor for pulmonary complications (odds ratio 2.49, 95% confidence interval 1.21-5.13).. Almost 20% of patients who received FFP for warfarin reversal developed pulmonary complications, primarily TACO, and this risk increased with > 3 units of FFP. Clinicians should be aware of and prepared to manage these complications.

    Topics: Acute Lung Injury; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Component Transfusion; Boston; Emergency Service, Hospital; Female; Hemorrhage; Humans; Incidence; International Normalized Ratio; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Plasma; Retrospective Studies; Risk Assessment; Risk Factors; Tertiary Care Centers; Time Factors; Warfarin

2016
Hemostatic therapy should be used for acute treatment of anticoagulation-related intracerebral hemorrhage.
    Stroke, 2012, Volume: 43, Issue:9

    Topics: Acute Lung Injury; Aged; Anticoagulants; Cerebral Hemorrhage; Factor VII; Female; Heart Valve Prosthesis; Hemostatic Techniques; Hemostatics; Humans; International Normalized Ratio; Plasma; Prothrombin; Transfusion Reaction; Warfarin

2012
A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:6

    Prothrombin complex concentrates (PCCs) and fresh-frozen plasma (FFP) have been clinically used for acute warfarin reversal. The recovery of prothrombin time (PT) or international normalised ratio (INR) is often reported as an endpoint, but haemostatic efficacies of PCCs and FFP may not be fully reflected in static clotting test in platelet-poor plasma. Using various in vitro assays, we compared the effects of two PCC preparations (3-factor PCC; Bebulin and 4-factor PCC; Beriplex) and FFP on warfarin reversal under static and flow conditions. First, we added an aliquot of either PCC (0.3 or 0.72 U/ml) or 20% FFP (v/v) to commercial warfarin plasma (INR 3.2, or 10.3), and then measured PT, factor II, factor VII, and thrombin generation. Subsequently, we collected whole blood samples from six consented warfarin-treated patients with mean INR 3.0 ± 0.5 (range 2.5-3.7), and compared clot formation under flow conditions at 280 s-1 before and after addition of either PCC preparation (0.3 and 0.6 U/ml) or 20% of FFP (v/v). PT/INR were restored by either PCC in plasma with INR 3.0, but they were more effectively corrected by 4-factor PCC than 3-factor PCC in plasma with INR 10.3. Effects of FFP were similar to 0.3 U/ml of PCCs in terms of PT, but FFP was less efficacious than PCCs in recovering thrombin generation or factor II levels. In flow experiments, the onset of thrombus formation was shortened by either PCC, but not by FFP, contrary to shortened PT values. For warfarin reversal 20% volume replacement with FFP is inferior to PCCs.

    Topics: Acute Lung Injury; Adult; Blood Coagulation; Blood Coagulation Factors; Blood Component Transfusion; Blood Flow Velocity; Drug Substitution; Hemostatics; Humans; International Normalized Ratio; Middle Aged; Plasma; Prothrombin Time; Thrombosis; Warfarin

2011